Radiotherapy Development Branch (RDB)

The Radiotherapy Development Branch (RDB) is one of the two branches of the Radiation Research Program,  a critical resource within the US government that fosters an improved understanding of the therapeutic utility of radiation and other forms of energy. 

RDB works closely with the Clinical Radiation Oncology Branch (CROB). It uses a variety of existing funding mechanisms and novel collaborations across NCI and NIH and partnering with other U.S. Government agencies. RDB supports basic, preclinical, and translational research related to improving the outcomes of radiation and drug combination treatments to cancer patients, safety, efficacy, and quality-of-life. It is a focal point for advancing basic and preclinical research in Radiation Oncology within NIH and NCI. 

The branch manages grants and collaborative agreements in a wide range of topics, including studies on Cellular Responses to Radiation, Radiation-Induced Normal Tissue Injury, Discovery and Development of Biomarkers and Predictive Assays, Radiation-Effect Modulators, Nanoparticles, Tumor Microenvironment, Radiation Immune Effects, Molecular Targeting, and Tumor Signaling. In addition to grants management, RDB is also involved in promoting radiobiology education.

Two Program Directors manage RDB’s grant portfolio. RDB conducts workshops to identify critical research gaps, develop consensus, and stimulate research in thrust areas. They advise, in their areas of expertise as below, potential applicants and grantees who perform cutting-edge research in Radiation Biology/Oncology.

Contact Information

Dr. Pataje G Prasanna, Ph.D.   --or--    Dr. Moly J. Aryankalayil, Ph.D.
240-276-5690                                       240-858-3002/240-426-1741
pat.prasanna@nih.gov                         aryankalayilm@mail.nih.gov